SCHEMBL17458579

SCHEMBL17458579

C[C@@H]1C[C@H](Cn2ccc3cc(-c4cn[nH]c4)ccc32)CN1S(=O)(=O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 10/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 1/20 0.37
GRM2 Q14416 1/20 0.36
BRD4 O60885 1/20 0.36
ABCB1 P08183 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ACP1 P24666 1/20 0.35
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
HTR7 P34969 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
ROCK2 O75116 1/20 0.34
GRK2 P25098 2/20 0.33
GRK1 Q15835 2/20 0.33
GRK5 P34947 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17458568 1.00 HTR6 (0.41) HTR6L3MBTL1POLBGRM2BRD4
SCHEMBL17458535 1.00 HTR6 (0.41) HTR6L3MBTL1POLBGRM2BRD4
SCHEMBL17464748 1.00 HTR6 (0.41) HTR6L3MBTL1POLBGRM2BRD4
SCHEMBL17458511 1.00 HTR6 (0.41) HTR6L3MBTL1POLBGRM2BRD4
SCHEMBL17458583 1.00 HTR6 (0.41) HTR6L3MBTL1POLBGRM2BRD4
SCHEMBL17464736 1.00 HTR6 (0.41) HTR6L3MBTL1POLBGRM2BRD4
SCHEMBL17464751 0.93 HTR6 (0.40) HTR6L3MBTL1POLBGRM2ABCB1
SCHEMBL17458565 0.92 KDM1A (0.38) HTR6L3MBTL1GRM2KMT2AHRH3
SCHEMBL17464772 0.92 KDM1A (0.38) HTR6L3MBTL1GRM2KMT2AHRH3
SCHEMBL17458585 0.92 KDM1A (0.38) HTR6L3MBTL1GRM2KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701663-B2 Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof INNOV17 LLC (US) 2017-07-11 US claimed
US-20160024056-A1 SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF INNOV17 LLC 2016-01-28 US claimed
US-9701663-B2 Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof INNOV17 LLC (US) 2017-07-11 US disclosed
US-9701663-B2 Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof INNOV17 LLC (US) 2017-07-11 US disclosed
WO-2016014910-A1 SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF INNOV17 LLC (US) 2016-01-28 WO disclosed
US-20160024056-A1 SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF INNOV17 LLC 2016-01-28 US disclosed
US-20160024056-A1 SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF INNOV17 LLC 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024056-A1 SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF RARA, RARB, RXRA HTR6 2847/4885L3MBTL1 3740/4885POLB 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.